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Cost-effectiveness of a stepped care
program to prevent depression among
primary care patients with diabetes mellitus
type 2 and/or coronary heart disease and
subthreshold depression in comparison
with usual care
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Abstract
Background: Patients with diabetes mellitus type 2 (DM2) and/or coronary heart disease (CHD) are at high risk to
develop major depression. Preventing incident major depression may be an important tool in reducing the
personal and societal burden of depression. The aim of the current study was to assess the cost-effectiveness of a
stepped care program to prevent major depression (Step-Dep) in diabetes mellitus type 2 and/or coronary heart
disease patients with subthreshold depression in comparison with usual care.
Methods: An economic evaluation with 12 months follow-up was conducted alongside a pragmatic cluster-
randomized controlled trial from a societal perspective. Participants received care as usual (n = 140) or Step-Dep
(n = 96) which consisted of four sequential treatment steps: watchful waiting, guided self-help, problem solving
treatment and referral to a general practitioner. Primary outcomes were quality-adjusted life years (QALYs) and
cumulative incidence of major depression. Costs were measured every 3 months. Missing data was imputed using
multiple imputation. Uncertainty around cost-effectiveness outcomes was estimated using bootstrapping and
presented in cost-effectiveness planes and acceptability curves.
Results: There were no significant differences in QALYs or depression incidence between treatment groups.
Secondary care costs (mean difference €1644, 95% CI €344; €3370) and informal care costs (mean difference €1930,
95% CI €528; €4089) were significantly higher in the Step-Dep group than in the usual care group. The difference in
total societal costs (€1001, 95% CI €-3975; €6409) was not statistically significant. The probability of the Step-Dep
intervention being cost-effective was low, with a maximum of 0.41 at a ceiling ratio of €30,000 per QALY gained
and 0.32 at a ceiling ratio of €0 per prevented case of major depression.
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Conclusions: The Step-Dep intervention is not cost-effective compared to usual care in a population of patients
with DM2/CHD and subthreshold depression. Therefore, widespread implementation cannot be recommended.
Trial registration: The trial was registered in the Netherlands Trial Register (NTR3715).
Keywords: Randomized controlled trial, Depression, Prevention, Cost-effectiveness analysis, Diabetes mellitus type 2,
Cardiovascular disease
Background
Major depression is a common mental health problem
in primary care that yearly affects approximately 3–9%
of the general population [1, 2], and about 10–14% of all
patients consulting their general practitioner (GP) [3]
over a year. Currently, major depression ranks fourth in
the list of diseases causing most disability as measured
in disability adjusted life years (DALYs) in industrialized
countries [4, 5]. It is expected that in 2030, depression
will be the second largest contributor to DALYs globally
[6]. Major depression is even more common in patients
with type 2 diabetes mellitus (DM2) and/or coronary
heart disease (CHD) with 12month incidence rates ran-
ging between 10 and 20% [7, 8]. Moreover, this combin-
ation of disorders leads to a substantial additional health
challenge, as it is associated with a higher burden of dis-
ease resulting in reduced quality of life [9–11], adverse
health outcomes [9–12], higher productivity losses [13–
15] and higher health care use [16–18] compared to only
having depression or DM2 and/or CHD [9–12, 16, 19].
Research has shown that the treatment success of
major depression is low [20, 21]. Thus, preventing major
depression is considered as a viable strategy to reduce its
personal and economic burden. Considering the higher
prevalence and chronicity of depression in patients with
DM2 and/or CHD compared to the general population,
prevention in this patient group could greatly reduce the
personal and economical burden [22].
Subthreshold depression, i.e., the presence of depres-
sive symptoms without fulfilling the criteria for major
depressive disorder, is the most important predictor of
major depression [23]. More than 40% of all DM2 and/
or CHD patients with subthreshold depression will de-
velop a major depressive disorder within two years [24,
25]. Moreover, subthreshold depression itself is associ-
ated with increased productivity losses [26] and health
care utilization, and lower quality of life [27, 28].There-
fore, treating subthreshold depression might be an ef-
fective strategy to prevent depression and the burden
associated with depressive symptoms.
Previous research has shown that psychological inter-
ventions aimed to reduce subthreshold depression may
prevent incident major depression [29]. Especially prom-
ising are interventions that are delivered in a stepped
care format in which upscaling to more extensive treat-
ment is only done when depressive symptoms remain
present [30]. Also, stepped care may prevent incident
major depression in older patients and patients with
chronic diseases who also experience subthreshold de-
pression, but the results are mixed at best [31–36]. Pre-
vious studies have shown that stepped care can be
effective to treat major depression in patients with DM2
and/or CHD [37]. However, whether stepped care is
cost-effective in preventing major depression in this
population is unknown.
Economic evaluations of stepped care programs to
prevent major depression are scarce. However, insight
into the investments needed per unit of gained effect are
urgently needed to decide whether the healthcare bene-
fits stepped care possibly offers are affordable [38]. Espe-
cially healthcare policy makers who need to decide
about the best way to spend the scarce resources avail-
able for healthcare have an urgent need for such infor-
mation [38]. Therefore, in this study we assessed the
cost-effectiveness of Step-Dep, a stepped care program
to prevent major depression in primary care patients
with DM2 and/or CHD who experience subthreshold
depressive symptoms, in comparison with care as usual
[39]. We hypothesized that Step-Dep would result in a
reduction in the incidence of major depression and soci-
etal costs as compared to usual care.
Methods
Study design and setting
This economic evaluation was conducted from a societal
perspective alongside the Step-Dep study; a cluster ran-
domized controlled trial with measurements at baseline
and 3, 6,9 and 12months. Step-Dep was conducted be-
tween 2013 and 2015. The clusters consisted of 27 pri-
mary care centers in the Netherlands with 53 general
practitioners (GPs) and 128,280 enlisted patients. The
total number of enlisted patients per center ranged be-
tween 2000 and 8000. Centers were recruited through
research networks of general practitioners. The Step-
Dep intervention consisted of a stepped care program to
prevent major depression in DM2/CHD patients with
subthreshold depressive symptoms. To resemble daily
practice as much as possible, the Step-Dep intervention
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was implemented by practice nurses who were already
working at the participating primary care center. Details
of the Step-Dep study are described elsewhere [39].
The study was performed in accordance with the dec-
laration of Helsinki (2008) and the Dutch Medical Re-
search involving Human Subjects Act (WMO). The
protocol was approved by the medical ethics committee
of the VU University Medical Centre (NL39261.029.12,
registration number 2012/223), and registered in the
Dutch Trial Register (NTR3715 http://www.trialregister.
nl/trialreg/admin/rctview.asp?TC=3715).
Randomization & blinding
Randomization was done at the level of the participating
primary care centers to avoid contamination between
the treatment groups. After consent to participate, a pri-
mary care center was randomly allocated to either the
intervention group or the care as usual group by an in-
dependent statistician using a computer-generated list of
random numbers. The statistician was blinded for the lo-
cation and other characteristics of the primary care cen-
ters. Centers were stratified for size (2000 to 5000
patients or > 5000 patients).
Participant selection
Patients could participate when they were diagnosed
with DM2 and/or CHD, and were experiencing
subthreshold depressive symptoms Patient Health
Questionnaire-9 (PHQ-9) [40] score of 6 or more [41,
42], without meeting the criteria for a major depressive
disorder according to the Mini International Neuro-
psychiatric Interview (MINI) [43]. Patients who were po-
tentially eligible were selected by constructing a
computer-generated list of all patients with an Inter-
national Classification of Primary Care (ICPC) diagnosis
of DM2 and/or CHD in the electronic patient record
system (Additional file 1). Patients were included by the
GP if they were considered to have cognitive impair-
ment, psychotic illness or terminal illness, antidepressant
medication use, loss of a significant other in the past 6
months, history of suicide attempts, visual impairment,
or otherwise not being able to complete written ques-
tionnaires or visit the primary care center. Potentially
eligible patients were invited by their GP to participate
in the study and to fill out a PHQ-9 form to screen for
depressive symptoms. Patients with a PHQ-9 score of
six or higher were contacted within 2 weeks by trained
research assistants after giving informed consent for a
telephone interview. The research assistants adminis-
tered the Mini International Neuropsychiatric Interview
(MINI) to rule out current major depressive disorder.
All patients who had a PHQ-9 score of 6 or more, did
not meet the criteria for major depression according to
the MINI, and provided informed consent were
included.
Intervention
The Step-Dep intervention was added onto usual care
and comprised four sequential treatment steps with in-
creasing intensity and a duration of 3 months each. After
each step, the practice nurse evaluated depressive symp-
toms using the PHQ-9. The next step was initiated when
a participant continued to experience subthreshold
depression (PHQ-9 > = 6), otherwise watchful waiting
was continued. When subthreshold depression (PHQ-
9 > = 6) recurred after any period of remission, the next
sequential step a participant had not yet received was of-
fered. Trained practice nurses acted as care manager
and coordinated the Step-Dep intervention. Practice
nurses were trained to use motivational interviewing
techniques to coach participants and to implement prob-
lem solving treatment (PST), and worked together with
the GP.
Step 1 was a period of watchful waiting, which started
with an introduction by the practice nurse. In this step,
no active interventions were implemented by the prac-
tice nurse besides monitoring of depressive symptoms.
In step 2 a guided self-help course was offered [44].
The practice nurse monitored progress of the partici-
pants during routine phone calls every other week.
Step 3 consisted of PST provided by the practice nurse
focusing on practical skill building [45, 46]. PST con-
sisted of a maximum of 7 sessions during 12 weeks.
In step 4, the participant was referred to the GP when
subthreshold depression was still present after complet-
ing the first 3 steps, and the participant still experienced
a need for care. This step was also initiated at any time
during the program, when a participant was diagnosed
with major depressive disorder or had suicidal thoughts.
Participants in the care as usual condition had unre-
stricted access to usual care as provided by their GP.
GPs and practice nurses in usual care centers did not re-
ceive any additional training or information about the
Step-Dep intervention. In general, GPs and practice
nurses follow Dutch guidelines for depression if they
suspect depressive symptoms. The Dutch guidelines for
depression recommend psychoeducation and short-
lasting psychological support for depressive complaints,
psychotherapy or antidepressants for major depressive
disorder, and psychotherapy and antidepressants for se-
vere major depressive disorder [47].
Effects
All participants received web-based questionnaires at
baseline, and at 3, 6, 9, and 12 months of follow up.
When participants preferred hard copies, the
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questionnaires were sent by mail to the home address of
the participant.
In the economic evaluation, the primary effect out-
comes were 12-month cumulative incidence of major
depression and Quality-Adjusted-Life-Years (QALYs).
The cumulative incidence of major depression was
assessed using the Dutch version of the MINI during
telephone interviews that were administered by trained
research assistants at 6 and 12months [48]. Quality of
life was measured using the EuroQol-5D-5L (EQ-5D-5L)
at 3, 6, 9, and 12 months follow up [49]. The EQ-5D
health states were converted to utility scores using the
Dutch EQ-5D tariff [50]. Utility scores represent the
relative desirability of a health state and are anchored at
0 (death) and 1 (best possible health related quality of
life) [50]. QALYs were calculated by multiplying the util-
ities with the amount of time a participant spent in a
particular health state. Transitions between health states
were linearly interpolated.
Secondary outcomes were severity of depressive symp-
toms and perceived recovery from depressive symptoms.
Severity of depressive symptoms was measured with the
Dutch version of the PHQ-9 (range 0–27) with higher
scores indicating more severe depression [51]. The
PHQ-9 is widely used to measure depressive symptoms,
and was previously validated in patients with chronic
medical illnesses [52]. To indicate to what extent partici-
pants considered themselves to be recovered from de-
pressive symptoms, they completed a 7-point Likert
scale ranging from 1 (complete recovery) to 7 (worse
than ever) with a score of 4 indicating no perceived
change. For the purpose of the current study, the scores
on this scale are dichotomized with scores 1–3 indicat-
ing recovery and scores 4–7 indicating no recovery.
Costs
Costs were measured from a societal perspective, which
means all costs were considered regardless of who pays
for them [39]. Costs were converted to 2014 if necessary
using Dutch consumer price indexes [53].
Intervention costs
To calculate intervention costs, a bottom-up micro-
costing approach was used. More specifically, for each
participant who participated in the intervention, the
costs were estimated based on the treatment steps that
were initiated for each participant [54]. The intervention
costs consisted of all costs that were associated with im-
plementation and execution of the Step-Dep program
including the time the practice nurses spent preparing
for consultations, providing care and registering pro-
vided care; the costs associated with the allocation of
practice space during visits at the primary care center;
the telephone costs for making appointments and
guiding the self-help course; materials used for the self-
help course and PST; and the costs of consultations with
the GP.
Health care utilization costs
To measure healthcare utilization, an adapted version of
the TIC-P questionnaire was used [55] which was ad-
ministered every 3 months. Participants reported on the
health care they received (e.g., GP, physiotherapist, med-
ical specialist, psychologist, hospitalization and comple-
mentary care), medication (prescription and over the
counter) they used, and informal care (by informal care-
givers such as relatives, friends, and neighbors) they re-
ceived. Dutch standard cost prices were used when
available [56]. Otherwise, we used prices from Dutch
professional organizations. Medication was valued using
standard prices that were published by the Royal Dutch
Society for Pharmacy [57].
Productivity costs
Costs of productivity losses were also included. Absen-
teeism was measured using a single item in which partic-
ipants reported the number of sick days during the last 3
months. Costs per sick day were calculated by using the
mean wage per hour for every age group for men and
women separately [56] and multiplying this by the mean
number of hours a participant worked per day. The costs
associated with absenteeism were calculated using both
the friction costs and the human capital approach [56].
As none of the participants reported a consecutive sick-
ness absence of more than the friction period of 23
weeks, both approaches resulted in the same estimation
of absenteeism costs and are, therefore, not reported
separately. Presenteeism was assessed using a single
question in which participants reported on the number
of hours they would need to work extra to compensate
for productivity losses due to sickness while present at
work. Costs associated with presenteeism were calcu-
lated by multiplying this number of hours with the mean
wage per hour for the age group and gender of the par-
ticipant [56].
Statistical analyses
All analyses were carried out according to the intention-
to-treat principle using STATA version 12SE. Missing
data were imputed using multiple imputation according
to the Multiple Imputation by Chained Equations
(MICE) algorithm [58]. Predictive Mean Matching was
used to account for the skewed distribution of costs
[59]. Variables that were associated with missing data,
and variables that were associated with the outcomes,
were identified and included in the imputation model.
Also, all variables in the analysis model (costs, effects
and potential confounders) were included. The number
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of imputed datasets was increased until the loss of infor-
mation was less than 5% [59]. In total 10 datasets were
imputed. The subsequent analyses were performed on
each imputed dataset separately after which results were
pooled using Rubins rules [60].
To estimate cost and effect differences, seemingly un-
related regression analyses were performed, since
multilevel analyses were not necessary considering the
small intra class correlation within primary care centers
(7%). Incremental Cost Effectiveness Ratios (ICERs) were
calculated by dividing the differences in total societal
costs by the effect differences. Because the distribution
of cost data is usually severely skewed to the right, statis-
tical uncertainty surrounding the estimates was assessed
Fig. 1 Flow of participants through the trial
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Table 1 Baseline characteristics of the participants assigned to the intervention group (Step-Dep) or usual care group (control)
Characteristics Intervention (n = 96) Care as usual (n = 140)
Female 42 (43.8) 65 (46.4)
Age, mean (SD) 67.8 (9.2) 67.3 (10.5)
Marital status
Married/living together 55 (57.3) 67 (47.9)
Single/divorced/widowed 35 (36.5) 63 (45)
Not reported 6 (6.3) 10 (10.4)
Both parents born in the Netherlands 74/90 (82.2) 112/130 (86.2)
Rural residential area 42 (43.8) 57 (40.7)
Unemployed/sick 12/90 (13.3) 14/130 (10.8)
Level of education1
Low 33 (34.4) 56 (40)
Average 22 (22.9) 38 (27.1)
High 35 (36.5) 36 (25.7)
Not reported 6 (6.3) 10 (7.1)
Diabetes Mellitus type 2 (DM2) 60 (62.5) 90 (64.3)
Coronary Heart Disease (CHD) 58 (60.4) 90 (64.3)
DM2 and CHD 22 (22.9) 40 (28.6)
Number of chronic diseases, median (25th -75th percentile) 3 (2–5) 3 (2–5)
DM2 treated with insulin or oral medication 42/57 (73.7) 64/83 (77.1)
CHD treated with chronic medication 46/54 (85.2) 65/85 (76.5)
Current smoker 16/90 (17.8) 23/129 (17.8)
Alcohol use above norm2 29/90 (32.2) 34 /129 (26.4)
Exercise under norm3 56/90 (62.2) 85/129 (65.9)
BMI, mean (SD) 29.4 (6.8) 28.5 (5.6)
EQ-5D-5L, mean (SD) 9,6 (2.9) 9,4 (2,9)
Locus of Control, mean (SD) 8.3 (4.2) 7.6 (4.1)
Social support, mean (SD) 35.8 (9.0) 36.7 9.5)
Dysthymia 6 (6.3) 7 (5.0)
Nr of depression in history
0 35 (36.5) 65 (46.4)
1 14 (14.6) 11 (7.8)
2 or more 40 (41.7) 43 (30.7)
Not reported 7 (7.3) 21 (15)
Onset of depression after age of 55 38/89 (42.7) 63/121 (52.1)
PHQ-9 at baseline, mean (SD) 9.5 (3.1) 9.3 (3.2)
Depression HADS, mean (SD) 6.9 (3.9) 6.1 (3.7)
Anxiety HADS, mean (SD) 6.9 (3.7) 6.3 (3.9)
Figures are numbers (percentage) unless stated otherwise
BMI Body Mass Index, EQ-5D-5L Euroqol 5 dimensions 5 levels CHD coronary heart disease; DM2 diabetes mellitus type 2; HADS Hospital Anxiety and Depression
Scale; PHQ-9 Patient Health Questionnaire-9 NL The Netherlands; SD Standard Deviation
1 Low level of education = did not finish high school; average level of education = finished high school and/or vocational education; high level of education =
finished college or university
2 The norm for alcohol use is defined as drinking more than two standard units of alcoholic beverages on an average day for male participants. For female
participants this norm is defined as drinking more than one standard unit of alcoholic beverages on an average day
3 The norm for healthy physical activity is defined as medium to high intensity exercise during 30 or more minutes on five or more days a week during a
typical week
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using bias-corrected accelerated bootstrapping with
5000 replications. Subsequently, 95% confidence inter-
vals surrounding differences in total costs and disaggre-
gated costs were estimated. Bootstrapped cost-effect
pairs were plotted in cost-effectiveness planes to graph-
ically display the uncertainty surrounding the ICERs
[61]. Furthermore, Cost-Effectiveness Acceptability
Curves (CEACs) were estimated to depict the probability
of an intervention being cost effective as compared to
usual care for various maximum amounts of money de-
cision makers are willing to pay for a unit of gained ef-
fect (i.e. ceiling ratio) [62].
The main analysis consisted of a fully adjusted
model in which estimates were adjusted for baseline
values, gender, age and other possible confounders:
marital status, employment status, level of education,
co-existence of DM2 and CHD, alcohol use, number
of depressive episodes in history and age of onset of
depression [63].
Sensitivity analyses
To test whether the results of the main analysis were ro-
bust, two sensitivity analyses were performed. In the first
sensitivity analysis, a crude model was estimated con-
taining only the outcome and the group allocation, and
no baseline values or confounders. In the second sensi-
tivity analysis, a healthcare perspective was adopted [64].
In this perspective, only direct health care costs are
taken into account (primary care, secondary care, inter-
vention and medication costs).
Results
Participants
Figure 1 visualizes the participant flow. In total, 96
participants were included in the intervention group
and 140 in the usual care group. The uptake of the
intervention was relatively low [63]. Only 25 of all 96
participants (26%) who were included in the interven-
tion group proceeded to step 2, 9 participants (9%) to
step 3 and 3 participants (3%) were referred to the
GP (step 4) [63].
Baseline characteristics are summarized in Table 1. Of
all participants, 70 (73%) in the intervention group and
92 (66%) in the care as usual group had complete cost
and effect data for all time points. Only 26 participants
(11%) dropped out of the study before follow up was
complete and 48 participants (20%) missed one or more
measurements without being completely lost to follow
up. Participants with more different chronic medical ill-
nesses, and who had lower quality of life at baseline were
more likely to have missing data at some point of
follow-up.
Effects
Table 2 shows the effects in the two groups and the dif-
ference between them. The adjusted cumulative inci-
dence of major depression was 13.4% in the intervention
group and 11.6% in the usual care group. The difference
was not statistically significant (adjusted mean difference
0.2%; 95% Confidence Interval (CI) -12%; 7%). The dif-
ference in QALYs between the intervention and usual
Table 2 Mean crude health related costs per patient from a societal perspective and mean 12-month follow up
Mean (SE) intervention Mean (SE) usual care Mean difference (95% CI)
Outcomes
Cumulative incidence of depression 0.134 (0.013) 0.116 (0.019) 0.018 (− 0.077; 0.113)
QALY’s gained 0.709 (0.031) 0.708 (0.038) −0.001 (− 0.479; 0.457)
Change in severity of depressive symptoms −2.672 (0.416) − 2.768 (0.630) − 0.096 (− 1.454; 1.646)
Perceived recovery 0.569 (0.045) 0.572 (0.065) 0.027 (− 0.156; 0.162)
Costs
Step-Dep intervention costs €98 (€7) €0 (€0) €98 (€86; €112)
Primary care €2310 (€307) €3580 (€918) €-1270 (€- 4369; €32)
Secondary care €3509 (€658) €1865 (€329) €1644 (€344; €3370)
Informal care €3711 (€868) €1780 (€233) €1930 (€528; €4089)
Medication €997 (€132) €736 (€66) €261 (€34; €602)
Total direct costs from societal perspective €10,625 (€1362) €7961 (€1133) € 2664 (€-908; €6101)
Unpaid productivity €5775 (€945) €6889 (€931) €-1114 (€-3497; €1454)
Absenteeism €480 (€162) €713 (€200) €-316 (€-904; €168)
presenteeism €356 (€161) €672 (€217) €-232 (€-762; €253)
Total indirect costs €6611 (€1028) €8274 (€994) € -1474 (€-3924; €1182)
Total societal perspective costs €17,236 (€2137) €16,235 (€1632) € 1001 (€-3975; €6409)
CI Confidence interval; SE Standard Error; NHS National Health Service (United Kingdom)
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care group was small and not statistically significant
(mean difference 0.002, 95% CI -0.41; 0.46). Differences
in change in depression severity and perceived recovery
between the intervention and control group were also
small and not statistically significant (Table 2).
Costs
In Table 2, the mean unadjusted costs per participant
are presented. The costs of the intervention were 98
euro. Secondary care costs (mean difference €1644, 95%
CI €344; €3370) and informal care costs (mean differ-
ence €1930, 95% CI €528; €4089) were statistically sig-
nificantly higher in the intervention group than in the
usual care group. Differences in costs for all other cost
categories were not statistically significant. Total societal
costs in the intervention group were higher than in the
usual care group (mean difference €1001, 95% CI
€-3975; €6409), but this difference was not statistically
significant.
Cost-effectiveness analyses
For the 12-month cumulative incidence of major depres-
sion, the ICER was − 46,802 €/prevented case of major de-
pression, indicating that the intervention was more costly
and less effective than usual care (Table 3). Although the
majority of cost-effect pairs (49%) were situated in the NE
quadrant, the CE plane shows that the cost-effect pairs
were distributed across all 4 quadrants of the CE plane in-
dicating that statistical uncertainty around the estimates is
large (Fig. 2a). The CEAC shows that the maximum prob-
ability of the intervention being cost effective is 32% at a
ceiling ratio of 0 €/prevented case of major depression






ICER Distribution of the Cost-Effectiveness plane (%)
North-East South-East South-West North-West
Main analysesa




−0.024 (− 0.118; 0.070) −46,802 19% 11% 21% 49%
QALYs (EQ-5D) €919
(€-3133; €5145)





0.077 (−1.546; 1.701) 11,927 32% 23% 12% 33%
Perceived recovery €1125
(€-2987; €5343)
0.011 (−0.156; 0.177) 107,353 38% 17% 14% 31%
Sensitivity analyses 1: Crude analysesb




−0.018 (− 0.113; 0.077) −55,779 20% 16% 20% 44%
QALYs (EQ-5D) € 1001
(€-3547; €5780)





0.096 (−1.646; 1.454) 10,429 32% 23% 12% 33%
Perceived recovery € 1001
(€-3540; €5800)
−0.027 (− 0.162; 0.156) − 373,720 32% 17% 19% 32%





−0.024 (− 0.118; 0.070) −58,733 27% 3% 5% 65%
QALYs (EQ-5D) €1369
(€-590; 3110)





0.077 (−1.541; 1.695) 18,174 49% 6% 3% 42%
Perceived recovery €1422
(€-541; 3173)
0.0126 (−0.153; 0.179) 112,624 53% 4% 4% 39%
CI Confidence Interval; MINI Mini International Neuropsychiatric Interview; EQ-5D-5L EuroQo-5Dimensions 5 Levels; PHQ-9 Patient Health Questionnarie-9; NHS
National Health Service (United Kingdom)
a Costs from a societal perspective are analyzed. All analyses are corrected for baseline values of costs from a societal perspective and the effect, gender, age and
other possible confounders: marital status, employment status, level of education, co-existence of DM2 and CHD, alcohol use, number of depressive episodes in
history and age of onset of depression
b Costs from a societal perspective are analyzed. The analyses are not corrected for baseline values of costs and effects, nor for possible confounders
c Costs from a NHS perspective are analyzed. All analyses are corrected for baseline values of costs from NHS perspective and the effect, gender, age and other
possible confounders: marital status, employment status, level of education, co-existence of DM2 and CHD, alcohol use, number of depressive episodes in history
and age of onset of depression
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(Fig. 2b). Because the intervention was less effective than
usual care, the probability of cost-effectiveness decreased
with higher ceiling ratios.
The cost-utility ratio was 88,898 €/QALY, indicating
that €88,898 needs to be paid to gain one QALY in the
intervention group as compared to the usual care group.
Cost-effect pairs were distributed over all four quadrants
of the CE plane, indicating substantial statistical uncer-
tainty around costs and effects (Fig. 3a). The CEAC (Fig.
3b) shows that the maximum probability of the Step-
Dep intervention being cost effective in the intervention
group as compared to the usual care group is 41% at a
ceiling ratio of 30,000 €/QALY.
The results of the analyses for severity of depressive
symptoms are comparable to those for the cumulative
incidence of depression (Table 3). The results of the
analyses for perceived recovery are similar to the results
for QALYs (Table 3).
Sensitivity analyses
Results from the crude analyses were similar to the re-
sults of the main analyses. Using the healthcare perspec-
tive, the cost difference between the groups was larger
than in the main analysis; €2664 instead of €1001 (un-
adjusted estimates; Table 2). Therefore, in these analyses
the ICER estimates are larger and a greater proportion
Fig. 2 a Cost-effectiveness plane visualizing the uncertainty surrounding the incremental cost-effectiveness ratio for cumulative depression in the
main analysis; (b) Cost-effectiveness acceptability curve visualizing the probability of the intervention being cost effective at different values of
willingness to pay in Euros for cumulative depression in the main analysis
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of cost-effect pairs are situated in the northern quad-
rants of the CE plane compared to the main analysis.
Thus, from the healthcare perspective the stepped care
program was even less cost-effective in comparison with
usual care than from the societal perspective.
Discussion
This study shows that the Step-Dep intervention for the
prevention of major depression in primary care partici-
pants with DM2 and/or CHD and subthreshold depres-
sion is not cost-effective in comparison with usual care.
The results of the current study are contrasting with
previous studies that evaluated the cost-effectiveness of
comparable stepped care interventions to prevent major
depression [65] and to treat subthreshold depression
[66]. The main difference with these previous studies is
the lack of effectiveness of the Step-Dep intervention
and the lower than expected risk of developing depres-
sion in both arms.
In the Dutch primary care system, participants with
DM2 and/or CHD are seen regularly by their GP and/or
practice nurse, and care givers are expected to ask par-
ticipants about their mental health during these consul-
tations. When a participant reports problems in this
area, psychological care may be offered [67]. This may
have diminished the contrast between the study groups.
Fig. 3 a Cost-effectiveness plane visualizing the uncertainty surrounding the incremental cost-effectiveness ratio for QALYs in the main analysis;
(b) Cost-effectiveness acceptability curve visualizing the probability of the intervention being cost effective at different values of willingness to
pay in Euros for QALYs in the main analysis
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However, utilization rates of mental healthcare services
and psychotropic medication in both groups were low,
and did not differ much between groups (data not
shown). In this study, secondary and informal health
care costs were significantly higher in the intervention
group than in the usual care group, while primary care
costs were lower. Perhaps intervention participants fo-
cused on other aspects of their health than normally and
shifted their attention to more different health domains,
which could have led to different care seeking behavior
outside primary care.
There is substantial evidence showing the effectiveness
of stepped care interventions for the treatment of
depression [68], although the evidence regarding cost-
effectiveness is less convincing [69]. When looking at
stepped care interventions for the prevention of depres-
sion, however, results are more conflicting. Studies among
geriatric populations and visually disabled populations
showed that stepped care reduced the incidence of depres-
sion [31–33], whereas other studies showed no effect [35,
36, 70]. Results on the cost-effectiveness of these interven-
tions differed, with one study showing that stepped care
was dominant over usual care [71], one study showing
that stepped care was associated with health benefits at af-
fordable costs [65], and one study showing that stepped
care was not cost-effective [72]. Our study was in line with
the studies showing that stepped care is not effective nor
cost-effective in comparison with usual care. Possible ex-
planations for these findings are that symptoms of depres-
sion may be overlapping with symptoms of DM2 and/or
CHD and that the uptake of the stepped care intervention
was low in our study.
This study has several strengths. First, to our know-
ledge, it is the first to evaluate the cost-effectiveness of a
stepped care approach to prevent the onset of major
depression in participants with DM2 and/or CHD with
subthreshold depression. Second, there was a long
follow-up period (12 months), while the number of
dropouts was low (n = 26, 11%). This minimizes the
chances of attrition bias. Third, the pragmatic design
and implementation of the intervention maximizes the
generalizability of the results to daily practice. Fourth,
we evaluated the cost-effectiveness of the Step-Dep
intervention from a societal perspective, taking in ac-
count all health-related costs, but also costs of informal
care and lost productivity. This is more informative for
decision makers in health care than narrower perspec-
tives, since shifting of resources between different sec-
tors becomes clear.
However, there are also some limitations to our study.
First, blinding of caregivers and participants was not
possible due to the nature of the intervention. Addition-
ally, as with all cost-effectiveness studies, it is difficult to
generalize the results outside of the researched health
care system (the Dutch health care system in this case).
Also, the implementation rate of the intervention was
relatively low [63]. This was partly due to the improve-
ment in depressive symptoms in both groups after inclu-
sion making referral to more intensive treatment steps
unnecessary. This is in contrast with the results of the
process evaluation conducted alongside this study that
showed that practice nurses considered the intervention
beneficial for participants’ overall wellbeing [73]. Pos-
sibly, the need for care in the selected population was
low, compromising the contrast between treatment
groups. This may also mean that participants in the
usual care group received more intensive treatment than
in the intervention group. If this was the case, this
should be reflected in the healthcare utilization cost in
the usual care group, but these did not differ signifi-
cantly between groups (data not shown). With a larger
implementation rate, effects of the intervention might
have been larger and costs higher. However, total costs
could become lower when participants receive more ad-
equate treatment for their depression, and thus seek less
care elsewhere, for example in (more expensive) second-
ary care. Moreover, more effective treatment may be as-
sociated with reduced morbidity in the long term.
Finally, the study’s power was based on the expected in-
cidence rate of major depression. However, this inci-
dence was much lower than expected. Additionally,
because of the skewed distribution of costs larger sample
sizes are generally needed than for clinical effects [74].
Conclusions
Based on the current results, we conclude that the Step-
Dep intervention is not cost-effective compared to usual
care. The results of this study do not support widespread
implementation of the Step-Dep intervention. However,
it should be considered that treatment uptake was low
and that the study was underpowered. Further research
could show whether stepped care to prevent depression
is more beneficial among the subgroup of people who
express a need for treatment for their depressive
symptoms.
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